MellingMedical Welcomes Black Forest Medical Group to Its Select Portfolio of Medical Products Providers

admin

MellingMedical today announced a new distribution relationship with Black Forest Medical Group, Inc., that will provide a pathway into the federal health care system for the company’s cutting edge neurosurgical devices. As an SBA-Verified Service-Disabled Veteran-Owned Small Business (SDVOSB) with extensive experience in federal contracting, MellingMedical can provide a vital avenue for delivering innovation.

“Black Forest Medical Group brings to the table a remarkable mix of surgeon-driven insights and incredible engineering precision that makes them unique in the marketplace,” said Chris Melling, founder and CEO of MellingMedical. “Their cranial stabilization and brain retractor solutions will make a difference with neurosurgeons and their teams across the federal health care system.”

Black Forest Medical Group, GmbH, was founded in 1995 with a core focus on cranial stabilization and retractor systems for standard and intraoperative imaging neurosurgical applications. Since then, their product portfolio has grown to include a wide range of accessories and customized products. Black Forest Medical Group, Inc., has been operating in the US as the sole distributor of the DORO brand of neurosurgical products since 2003.  Their cooperation with distributors and well-known surgeons worldwide helps BFMG to continuously improve their products and services while enhancing neurosurgery with new, high-quality innovations.

“We are delighted to join forces with a high-integrity company like MellingMedical as we seek to offer our products to the federal health care system,” said Mark Budde, Vice President & General Manager of Black Forest Medical Group, Inc. “Melling’s reputation for playing by the rules and their dedicated support of America’s soldiers and veterans made them the obvious partner for us.  We see a bright future for this relationship and the facilities we’ll serve together.”

Next Post

HNL Lab Medicine Begins Subtyping Positive Flu A Samples for H5N1 Avian Influenza

In response to updated recommendations from the Centers for Disease Control and Prevention, HNL Lab Medicine will begin subtyping all positive influenza A samples from hospitalized patients to detect H5N1 Highly Pathogenic Avian Influenza. This enhanced surveillance effort is part of a broader initiative to monitor potential bird flu cases […]
thehealthco